Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors.

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2018-09-28 eCollection Date: 2018-04-01 DOI:10.2217/hep-2017-0025

Leyre Zubiri, José I Bilbao, Javier Rodríguez, Bruno Sangro

引用次数: 3

Abstract

The hormone secretion in pancreatic neuroendocrine tumors (pNET) causes an important interference in patients' quality of life. We present two cases of pNET metastatic to the liver (a pancreatic endocrine carcinoma with a severe hormonal syndrome and an insulinoma with severe crisis of hypoglycemia and coma) refractory to conventional treatments, which were finally solved with selective internal radiation therapy (SIRT), a nonstandard level 1 therapy. We show two examples of an excellent control of symptoms together with a long survival after treatment with SIRT. The evidence supporting the use of this therapy is level 2. Our case reports strongly support the use of SIRT for the severe clinical syndrome in pNET metastatic to the liver and refractory to somatostatin analogs.

Abstract Image

查看原文本刊更多论文

选择性内放射治疗:胰腺神经内分泌肿瘤激素综合征的有效治疗方法。

胰腺神经内分泌肿瘤(pNET)的激素分泌是影响患者生活质量的重要因素。我们报告了2例pNET转移到肝脏的病例(1例胰腺内分泌癌伴严重激素综合征，1例胰岛素瘤伴严重低血糖和昏迷危像)，常规治疗难治性，最终通过选择性内放射治疗(SIRT)解决，这是一种非标准的1级治疗。我们展示了两个在SIRT治疗后症状得到良好控制和长期生存的例子。支持使用这种疗法的证据是2级。我们的病例报告强烈支持使用SIRT治疗pNET转移到肝脏和对生长抑素类似物难治的严重临床综合征。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.